7 hasil untuk "Qi-Rong Geng"
Menampilkan 1–7 · 0,50 detik · RSS
-
Artikel Jurnal Teks lengkap
Serum Levels of Interleukin-9 Correlate with Negative Prognostic Factors in Extranodal NK/T-Cell Lymphoma
Interleukin-9 (IL-9) is more functionally diverse than previously expected, especially with regards to lymphomagenesis. However, the relationship between IL-9 and the clinicopathological features of extranodal NK/T-cell lymphoma is less well established. Patients with this lymphoma in Sun Yat-Sen…
Juga tersedia di: DOAJ
-
Artikel Jurnal Teks lengkap
Beclin-1 Expression Is a Significant Predictor of Survival in Patients with Lymph Node-Positive Gastric Cancer
Background: Beclin 1 is a main actor of autophagy. The expression of Beclin 1 and its prognostic role in gastric cancer is largely unexplored. The purpose of the present study is to investigate the expression of beclin 1 in gastric cancer cells, tissues and its relationship with prognosis. Methods…
Juga tersedia di: DOAJ
-
Artikel Jurnal
ENO2 Promotes Cell Proliferation, Glycolysis, and Glucocorticoid-Resistance in Acute Lymphoblastic Leukemia
Background/Aims: The metabolic features of cancer cells have long been acknowledged to be altered and to provide new therapeutic opportunities. The expression of glycolytic enzyme enolase 2 (ENO2) was found to be closely associated with the clinical features of acute lymphoblastic leukemia (ALL)…
-
Artikel Jurnal
New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study
Abstract Background In patients with diffuse large B-cell lymphoma (DLBCL), central nervous system (CNS) relapse is uncommon but is nearly always fatal. This study aimed to determine the risk factors for CNS relapse in DLBCL patients and to evaluate the efficacy of rituximab and intrathecal…
-
Artikel Jurnal
XELOX doublet regimen versus EOX triplet regimen as first‐line treatment for advanced gastric cancer: An open‐labeled, multicenter, randomized, prospective phase III trial (EXELOX)
Abstract Background There is no consensus on whether triplet regimen is better than doublet regimen in the first‐line treatment of advanced gastric cancer (AGC). We aimed to compare the efficacy and safety of oxaliplatin plus capecitabine (XELOX) and epirubicin, oxaliplatin, plus capecitabine (EOX)…